Genzyme "outperform"

12/20/07 - Robert W. Baird

NEW YORK, December 20 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on Genzyme Corporation (GENZ). The target price is set to $84.

In a research note published this morning, the analysts mention that the Phase II data for Amicus’ Amigal drug, which competes with Genzyme’s Fabrazyme for the treatment of Fabry's disease, indicated that the drug is effective on both lower and higher enzyme-level patients. The data for Amigal was less effective, however, than that for Fabrazyme, which implies a decline in the risk to Genzyme’s drug, the analysts say.